IceCure Medical Ltd (ICCM) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.
The consensus price target is $3.51 (low: $2.00, high: $5.75), representing an upside of 889.6% from the current price $0.35.
Analysts estimate Earnings Per Share (EPS) of $-0.28 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.31 vs est $-0.28 (missed -11.5%). 2025: actual $-0.24 vs est $-0.23 (missed -4.3%). Analyst accuracy: 93%.
ICCM Stock — 12-Month Price Forecast
$3.51
▲ +889.57% Upside
Average Price Target
Based on 2 Wall Street analysts offering 12-month price targets for IceCure Medical Ltd, the average price target is $3.51, with a high forecast of $5.75, and a low forecast of $2.00.
The average price target represents a +889.57% change from the last price of $0.35.
Highest Price Target
$5.75
Average Price Target
$3.51
Lowest Price Target
$2.00
ICCM Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to IceCure Medical Ltd in the past 3 months
EPS Estimates — ICCM
93%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.31
vs Est –$0.28
▼ 10.3% off
2025
Actual –$0.24
vs Est –$0.23
▼ 4.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ICCM
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.003B
vs Est $0.003B
▼ 6.0% off
2025
Actual $0.003B
vs Est $0.003B
▼ 0.6% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
